Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer - Poll - MDSpire

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • By

  • June 24, 2026

  • 4 min

Share

Original Source(s)

Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

  • by

  • June 24, 2026

Related Content

The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

  • June 25, 2026

  • 1 min
Case Study: BRCA Mutation Led To Early Detection of Pre-Ovarian Cancer Condition

A 59-year-old woman was referred to Nicole Gaulin, MD, a gynecologic oncologist at Roswell Park Comprehensive Cancer Center, after learning she had a BRCA2 mutation linked with both breast cancer in a cousin and colon cancer in her father.

  • June 24, 2026

  • 1 min
2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min